Business Wire

GALDERMA

20.9.2022 10:01:42 CEST | Business Wire | Press release

Share
Galderma Debuts The Sensitive Skincare Faculty, a Global Expert Group to Improve Understanding and Management of Sensitive Skin

Reinforcing its commitment to advancing dermatology for every skin story, Galderma announced today the formation of a global Sensitive Skincare Faculty, which will focus its efforts on helping people with sensitive skin live better lives through focusing on three key pillars of research, innovation and engagement that play a key role in improving the broad understanding and management of sensitive skin. Comprised of 13 experts from across the world, the group will have representation from diverse geographies including China, Brazil, the Philippines, Germany, France, Australia, Italy and the United States (U.S.).

 

“We want people to feel in control of their skin, and this is especially important for those who have skin conditions that are often misunderstood – like sensitive skin.
We’re delighted to bring together such an esteemed group of experts from around the world who will collaborate to propose and implement research, innovation and educational projects
to advance the science of sensitive skin and bring positive changes to the whole community.”

 

WALTER GEIGER
CONSUMER CARE GLOBAL BUSINESS UNIT HEAD, GALDERMA

 

Sensitive skin is a complex and often interconnected condition, requiring personalized care and products specifically designed for it. More than seventy percent of people worldwide diagnose themselves as having sensitive skin, which can negatively impact quality of life and leave them feeling frustrated and looking for better solutions.i There is a need for science-backed guidance and advice on how to identify and care for sensitive skin of all kinds, to help improve the overall quality of sensitive skin.

The Sensitive Skincare Faculty will focus on three core pillars of activities:

  • Research – expanding the understanding of sensitive skin by filling evidence gaps and advancing in emerging areas
  • Innovation – inspiring the development of new solutions to improve diagnosis and care
  • Engagement – enhancing the knowledge of healthcare professionals to shape the future of best practice

In partnership with the Department of Dermatology at the George Washington University School of Medicine and Health Sciences, two grants have been awarded to accelerate the mission of the Sensitive Skincare Faculty. The first will establish a Galderma Sensitive Skin Translational Research Fellowship Program over five years to support medical students interested in expanding their research skill set into sensitive skin. The second project, the Galderma Skin Research Acceleration Fund, will span two years and look specifically at establishing a standard definition of sensitive skin.

 

“Our goal is to transform the science of sensitive skin into actionable insights and practical advice
that will empower everyone – from consumers and patients to healthcare professionals – to make positive strides forward.
We’re bringing together the latest information backed by science and making it available and accessible to everyone who needs it.”

 

PROFESSOR ADAM FRIEDMAN
CO-CHAIR, SENSITIVE SKINCARE FACULTY,
PROFESSOR AND CHAIR OF DERMATOLOGY,
THE GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES

 

Faculty members include Adam Friedman (co-chair, U.S.), Giovanni Pellacani (Italy), Martina Kerscher (Germany), Aaron Farberg (U.S.), Flávia Alvim Sant’Anna Addor (Brazil), Belinda Welsh (Australia), Yan Wu (China), Flordeliz Abad-Casintahan (Philippines), Adelaide Hebert (U.S.), Xiang Leihong (China), Laurent Misery (France), Joachim Fluhr (Germany) and Leona Yip (Australia).

The faculty’s inaugural meeting took place at the European Academy of Dermatology and Venereology congress in Milan, where members also participated in a Galderma-sponsored symposium on sensitive skin insights and management approaches.

About Galderma
Galderma is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermo-cosmetics and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we’re in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.

References:
iChen W, Dai R, Li L. The prevalence of self‐declared sensitive skin: a systematic review and meta‐analysis. Journal of the European Academy of Dermatology and Venereology. 2020 Aug;34(8):1779-88.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220920005039/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 10:01:00 CEST | Press release

Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye